Volume 13, Number 4—April 2007
Dispatch
Endpoints for Lymphatic Filariasis Programs
Caroline A. Grady*, Madsen Beau de Rochars†, Abdel N. Direny†, Jean Nicolas Orelus†, Joyanna Wendt*, Jeanne Radday*, Els Mathieu*, Jacquelin M. Roberts*, Thomas G. Streit‡, David G. Addiss*, and Patrick J. Lammie*
Table
Drug coverage for Leogane Commune, Haiti
| 2000 | 2001 | 2002 | 2003 | 2004 | |
|---|---|---|---|---|---|
| No. treated* | 74,000 | 55,000 | 94,000 | 102,000 | 122,000 |
| Reported coverage† | 69% | 50% | 84% | 89% | 104% |
| Surveyed coverage‡ | 71% | NA | 79% | NA | NA |
| Adverse events§ | 23% | 16% | 9% | 8% | 3% |
*Based on tally counts from distribution posts.
†Using 108,000 as the total population of Leogane determined by cluster survey in 2000, adjusted for annual population growth.
International Data Base (IDB): available from http://www.census.gov/ipc/www/idbprint.html
‡Published data (7,8)
§Based on the number of persons who reported to distribution posts with reportts adverse events as a percentage of the reported coverage. See reference (9) for a more detailed discussion of adverse events associated with the first round of mass drug administration..
